Phase 2Completed

Study to Evaluate the Effect of Obicetrapib in Combination With Ezetimibe as an Adjunct to HIS Therapy (ROSE2)

A Placebo-Controlled, Double-Blind, Randomized, Phase 2 Study to Evaluate the Effect of Obicetrapib 10 mg Daily in Combination With Ezetimibe 10 mg Daily as an Adjunct to High-Intensity Statin Therapy: The ROSE 2 Study

Sponsor
NewAmsterdam Pharma (Industry)
Enrollment
119 enrolled
Conditions
Dyslipidemias; High Cholesterol; Hypercholesterolemia
Interventions
Obicetrapib; Ezetimibe 10mg; Obicetrapib placebo; Ezetimibe placebo
Ages
adults, older adults
Registry
NCT05266586

Full record on ClinicalTrials.gov

From the registry

This study will be a placebo-controlled, double-blind, randomized, phase 2 study to evaluate the efficacy, safety, and tolerability of obicetrapib 10 mg, both in combination with ezetimibe 10 mg and as monotherapy, as an adjunct to high-intensity statin therapy.

Primary outcomes

  • Mean Percent Change in Low-Density Lipoprotein Cholesterol (LDL-C) for Combination Treatment Group Compared With the Placebo Group [Friedewald]
  • Median Percent Change in Low-Density Lipoprotein Cholesterol (LDL-C) for Combination Treatment Group Compared With the Placebo Group [Friedewald]
  • LS Mean Percent Change in Low-Density Lipoprotein Cholesterol (LDL-C) for Combination Treatment Group Compared With the Placebo Group [Friedewald]
  • Mean Percent Change in Low-Density Lipoprotein Cholesterol (LDL-C) for Combination Treatment Group Compared With the Placebo Group [PUC]

History

  1. Results first posted

  2. Last registry update

  3. Study completion

  4. Primary completion

  5. Started

  6. Registered